Today: 1 February 2026
Subscribe
Browse Category

NASDAQ:ANAB News 10 January 2026 - 11 January 2026

GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference

GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference

London, Jan 11, 2026, 08:35 GMT — The market has closed. Shares of GSK plc face fresh legal uncertainty on Monday after AnaptysBio moved to dismiss part of a contract claim related to royalties for the cancer drug Jemperli. On Friday, GSK slipped 0.26% to 1,886 pence, just shy of its 52-week peak at 1,909.5. Technical traders are eyeing the…
11 January 2026
·····
GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

New York, Jan 10, 2026, 03:42 EST — Market closed AnaptysBio said it filed a motion asking a U.S. court to dismiss part of a claim by GSK plc’s oncology unit, escalating a dispute over royalties tied to sales of cancer drug Jemperli, a PD-1 inhibitor — a kind of immunotherapy that helps the immune system attack tumours. Tesaro sued…
10 January 2026
·····

Stock Market Today

  • Dynamic Active Canadian Bond ETF (DXBC:CA) Market Analysis and Trading Signals - Feb 2026
    February 1, 2026, 4:24 AM EST. On February 1, 2026, the Dynamic Active Canadian Bond ETF (DXBC:CA) received neutral ratings across short, mid, and long-term horizons according to AI-generated signals. The trading plan suggests a buy near $21.75 with a target of $21.98 and a stop-loss at $21.64, while a short position is recommended near $21.98 targeting $21.75 with a stop-loss at $22.09. These signals reflect cautious market positioning in fixed income assets, highlighting the ETF's current stability. Market participants should note the updated timestamp and utilize these AI-driven insights with consideration of overall bond market conditions.
Go toTop